StimCardio Medical has raised $30.0M in Series A funding to advance its wearable neuromodulation platform, which pairs continuous physiological sensing with personalized therapy for use in daily life.
The company is starting with atrial fibrillation, aiming to restore autonomic balance and reduce AF burden through personalized peripheral neuromodulation. The round was backed by Metis Medtech and Catalyst Health Ventures.











